Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nucleoside Reverse Transcriptase Inhibitor · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Single Arm | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Nucleoside Reverse Transcriptase Inhibitor (NRTIs) | DRUG | in accordance with current clinical HIV treatment guidelines |
| ritonavir | DRUG | 100 mg bid orally, Days 1-14 |
| saquinavir [Invirase] | DRUG | 500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14 |
Inclusion Criteria: * Adult patients, \>/= 18 years of age * HIV-1 infection * Currently treatment-naïve and eligible to initiate a ritonavir-boosted Protease Inhibitor based regimen and willing and able to initiate saquinavir/ritonavir therapy for the first 14 days; the saquinavir/ritonavir regime...
Top 20 of 28 competitors
Nucleoside Reverse Transcriptase Inhibitor is an investigational small molecule being developed for the treatment of HIV Infections. It is currently in Phase 1 clinical development, meaning it has not yet been approved and is still being studied for safety and efficacy in patients.
Nucleoside Reverse Transcriptase Inhibitor is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical research on this investigational drug for HIV Infections.
Nucleoside Reverse Transcriptase Inhibitor is in Phase 1 clinical development. It is an investigational drug for HIV Infections and has not been approved by regulatory authorities. One Phase 1 trial has been completed, involving 23 participants.
Nucleoside Reverse Transcriptase Inhibitor has one completed clinical trial, NCT01638650, titled 'A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients.' This Phase 1 study enrolled 23 participants in the United Kingdom and was not randomized or double-blind.
The clinical trial NCT01638650 for Nucleoside Reverse Transcriptase Inhibitor studied ritonavir-boosted Invirase (saquinavir) in treatment-naïve HIV-1 infected patients. However, the drug name provided is Nucleoside Reverse Transcriptase Inhibitor, and no alternative names have been specified for this investigational drug.